Drug Profile


Alternative Names: FIN-5; IPI-926; Patidegib topical gel - PellePharm; Saridegib

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Infinity Pharmaceuticals; PellePharm
  • Class Antineoplastics; Small molecules; Veratrum alkaloids
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chondrosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Basal cell nevus syndrome
  • Discontinued Chondrosarcoma; Head and neck cancer; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 31 Jul 2017 Adverse events and efficacy data from a phase II trial in Basal Cell Nevus Syndrome released by PellePharm
  • 31 Jul 2017 PellePharm plans a phase III trial for patidegib in USA, in January 2018
  • 24 Apr 2017 PellePharm completes a phase II trial in Basal Cell Nevus Syndrome (In adults, In the elderly) in United Kingdom (Topical) (NCT02762084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top